Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
3,799
Views
4
CrossRef citations to date
0
Altmetric
Oncology

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

Tobias Engel Ayer Botrela CIOP – Centro Integrado de Oncologia e Pesquisa, Poços de Caldas, BrazilORCID Iconhttps://orcid.org/0000-0001-9137-0637
ORCID Icon,
Márcia Datz Abadib MSD Brasil, São Paulo, Brazil
,
Laura Chabrol Haasb MSD Brasil, São Paulo, Brazil
,
Cássia Rita Pereira da Veigab MSD Brasil, São Paulo, Brazil;c Department of General and Applied Administration, Universidade Federal do Paraná, Curitiba, BrazilCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9219-6279
ORCID Icon,
Dominihemberg de Vasconcelos Ferreirab MSD Brasil, São Paulo, Brazil
&
Denis Leonardo Jardimd Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, BrazilORCID Iconhttps://orcid.org/0000-0003-4663-1521
ORCID Icon
Pages 291-298 | Received 06 Oct 2020, Accepted 26 Jan 2021, Published online: 01 Mar 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.